

Thierry Soussi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1525443/thierry-soussi-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179
papers

13,021
citations

63
h-index

111
g-index

228
ext. papers

14,007
ext. citations

8.3
avg, IF

6.36
L-index

#	Paper	IF	Citations
179	TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
178	Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia Data Mining Mutation Databases.. <i>Frontiers in Oncology</i> , 2022 , 12, 808886	5.3	0
177	Evolutionary history of the p53 family DNA-binding domain: insights from an <i>Alvinella pompejana</i> homolog.. <i>Cell Death and Disease</i> , 2022 , 13, 214	9.8	0
176	Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon.. <i>Cancer Research</i> , 2022 , 82, 1492-1502	10.1	0
175	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. <i>Cell Death and Differentiation</i> , 2021 , 28, 1477-1492	12.7	4
174	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA Mutations-A Perspective from a Real-World Precision Medicine Cohort. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2612-2620	6.1	3
173	Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort. <i>British Journal of Haematology</i> , 2020 , 191, e90-e94	4.5	2
172	Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries. <i>Scientific Reports</i> , 2020 , 10, 20368	4.9	2
171	Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. <i>Genome Research</i> , 2019 , 29, 1555-1565	9.7	16
170	Fam83F induces p53 stabilisation and promotes its activity. <i>Cell Death and Differentiation</i> , 2019 , 26, 2125-2138	9.7	9
169	Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl Ketoglutarate. <i>Cell Reports</i> , 2019 , 27, 820-834.e9	10.6	22
168	Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux. <i>Cell Death and Disease</i> , 2019 , 10, 242	9.8	10
167	High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering. <i>Human Mutation</i> , 2019 , 40, 516-524	4.7	10
166	Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. <i>Cell Reports</i> , 2019 , 28, 1370-1384.e5	10.6	161
165	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019 , 28, 132-144.e3	10.6	45
164	The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants. <i>Blood</i> , 2019 , 134, 3021-3021	2.2	
163	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. <i>Nature Communications</i> , 2019 , 10, 5385	17.4	23

162	Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. <i>Human Mutation</i> , 2018 , 39, 925-933	4.7	17
161	ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. <i>Leukemia</i> , 2018 , 32, 1070-1080	10.7	93
160	Emergence and evolution of mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018 , 103, e143-e146	6.6	24
159	MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival. <i>Trends in Cancer</i> , 2018 , 4, 602-605	12.5	3
158	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple alterations. <i>Haematologica</i> , 2018 , 103, e13-e16	6.6	17
157	Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice. <i>Cancer Research</i> , 2017 , 77, 1250-1260	10.1	45
156	Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. <i>Human Mutation</i> , 2017 , 38, 339-342	4.7	16
155	TP53 and 53BP1 Reunited. <i>Trends in Cell Biology</i> , 2017 , 27, 311-313	18.3	2
154	TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. <i>International Journal of Cancer</i> , 2016 , 139, 1759-63	7.5	13
153	Genetic profiling of CLL: a TP53 addict's perspective. <i>Cell Death and Disease</i> , 2016 , 7, e2042	9.8	7
152	TP53: an oncogene in disguise. <i>Cell Death and Differentiation</i> , 2015 , 22, 1239-49	12.7	170
151	Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm. <i>Human Mutation</i> , 2014 , 35, 643-53	4.7	14
150	TP53 mutations in human cancer: database reassessment and prospects for the next decade. <i>Human Mutation</i> , 2014 , 35, 672-88	4.7	191
149	Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. <i>Human Mutation</i> , 2014 , 35, 766-78	4.7	25
148	The TP53 gene network in a postgenomic era. <i>Human Mutation</i> , 2014 , 35, 641-2	4.7	11
147	Analysis of TP53 mutation status in human cancer cell lines: a reassessment. <i>Human Mutation</i> , 2014 , 35, 756-65	4.7	110
146	The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. <i>Nucleic Acids Research</i> , 2013 , 41, D962-9	20.1	116
145	Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9551-6	11.5	66

144	TP53 mutations in human cancer: database reassessment and prospects for the next decade. <i>Advances in Cancer Research</i> , 2011 , 110, 107-39	5.9	57
143	Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011 , 1816, 199-208	11.2	12
142	The history of p53. A perfect example of the drawbacks of scientific paradigms. <i>EMBO Reports</i> , 2010 , 11, 822-6	6.5	31
141	TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. <i>Leukemia</i> , 2010 , 24, 2072-9	10.7	110
140	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010 , 95, 1973-6	6.6	109
139	MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. <i>Human Mutation</i> , 2010 , 31, 1020-5	4.7	23
138	Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. <i>FEBS Journal</i> , 2009 , 276, 4142-55	5.7	12
137	When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?. <i>Trends in Molecular Medicine</i> , 2009 , 15, 1-4	11.5	1
136	Mutant p53 protein localized in the cytoplasm inhibits autophagy. <i>Cell Cycle</i> , 2008 , 7, 3056-61	4.7	210
135	Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. <i>Cancer Biology and Therapy</i> , 2008 , 7, 699-708	4.6	82
134	Breast-cancer stromal cells with TP53 mutations. <i>New England Journal of Medicine</i> , 2008 , 358, 1635; author reply 1636	59.2	6
133	p53 alterations in human cancer: more questions than answers. <i>Oncogene</i> , 2007 , 26, 2145-56	9.2	189
132	Shaping genetic alterations in human cancer: the p53 mutation paradigm. <i>Cancer Cell</i> , 2007 , 12, 303-12	24.3	288
131	Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 944-54	3.1	24
130	Analysis of p53 Gene Alterations in Cancer: A Critical View 2007 , 255-292		4
129	Analysis of p53 Gene Alterations in Cancer: A Critical View 2007 , 255-292		
128	The UMD TP53 database and website: update and revisions. <i>Human Mutation</i> , 2006 , 27, 14-20	4.7	108
127	MUT-TP53: a versatile matrix for TP53 mutation verification and publication. <i>Human Mutation</i> , 2006 , 27, 1151-4	4.7	6

126	Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. <i>Annals of Oncology</i> , 2006 , 17, 842-7	10.3	76
125	Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. <i>Clinical Cancer Research</i> , 2006 , 12, 62-9	12.9	66
124	p53 mutation heterogeneity in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 331, 834-42	3.4	215
123	Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. <i>Human Mutation</i> , 2005 , 25, 6-17	4.7	115
122	UMD (Universal Mutation Database): 2005 update. <i>Human Mutation</i> , 2005 , 26, 184-91	4.7	91
121	The p53 pathway and human cancer. <i>British Journal of Surgery</i> , 2005 , 92, 1331-2	5.3	31
120	The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7518-28	2.2	301
119	A new set of monoclonal antibodies directed to proline-rich and central regions of p53. <i>Hybridoma</i> , 2004 , 23, 287-92		1
118	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study. <i>Clinical Cancer Research</i> , 2004 , 10, 3479-89	12.9	228
117	Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction. <i>Oncogene</i> , 2004 , 23, 5543-50	9.2	38
116	Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors. <i>Human Mutation</i> , 2004 , 24, 63-75	4.7	18
115	Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. <i>Cancer Biology and Therapy</i> , 2003 , 2, 559-63	4.6	14
114	Medullary Breast Carcinoma: Prognostic Implications of P53 Expression. <i>International Journal of Biological Markers</i> , 2003 , 18, 99-105	2.8	12
113	p53 mutations and resistance to chemotherapy: A stab in the back for p73. <i>Cancer Cell</i> , 2003 , 3, 303-5	24.3	27
112	Serum p53 antibodies in correlation to other biological parameters of breast cancer. <i>Cancer Detection and Prevention</i> , 2003 , 27, 182-6		19
111	ThinPrep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis: application to p53 mutation analysis. <i>Cancer</i> , 2003 , 99, 223-32	6.4	32
110	The UMD-p53 database: new mutations and analysis tools. <i>Human Mutation</i> , 2003 , 21, 176-81	4.7	123
109	Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. <i>Human Mutation</i> , 2003 , 21, 192-200	4.7	86

108	Splice mutations in the p53 gene: case report and review of the literature. <i>Human Mutation</i> , 2003 , 21, 101-2	4.7	42
107	Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway. <i>Oncogene</i> , 2003 , 22, 5082-90	9.2	11
106	Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. <i>Lung Cancer</i> , 2003 , 39, 297-301	5.9	22
105	Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. <i>Journal of Biological Chemistry</i> , 2003 , 278, 10546-55	5.4	34
104	Medullary breast carcinoma: prognostic implications of p53 expression. <i>International Journal of Biological Markers</i> , 2003 , 18, 99-105	2.8	5
103	An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue. <i>Oncogene</i> , 2002 , 21, 1909-21	9.2	37
102	Monoclonal antibodies raised against Xenopus p53 interact with human p73. <i>Oncogene</i> , 2002 , 21, 1304-8	9.2	4
101	Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. <i>Gastroenterology</i> , 2002 , 123, 492-504	13.3	117
100	The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. <i>Gene</i> , 2002 , 282, 207-14	3.8	55
99	Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line. <i>Oncogene</i> , 2001 , 20, 3766-75	9.2	12
98	Detection of p73 antibodies in patients with various types of cancer: immunological characterization. <i>British Journal of Cancer</i> , 2001 , 84, 57-63	8.7	19
97	A monoclonal antibody against DNA binding helix of p53 protein. <i>Oncogene</i> , 2001 , 20, 1398-401	9.2	5
96	Assessing TP53 status in human tumours to evaluate clinical outcome. <i>Nature Reviews Cancer</i> , 2001 , 1, 233-40	31.3	529
95	Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. <i>Lung Cancer</i> , 2001 , 31, 17-23	5.9	16
94	Gène et cancer: aspects fondamentaux et cliniques. <i>Cancer Radiothérapie: Journal De La Société Française De Radiothérapie Oncologique</i> , 2001 , 5, 36s-41s	1.3	
93	The p53 tumor suppressor gene: from molecular biology to clinical investigation. <i>Annals of the New York Academy of Sciences</i> , 2000 , 910, 121-37; discussion 137-9	6.5	210
92	p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1465-73	2.2	155
91	Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. <i>International Journal of Cancer</i> , 2000 , 89, 81-6	7.5	33

90	p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. <i>Human Mutation</i> , 2000 , 15, 105-13	4.7	207
89	UMD (Universal mutation database): a generic software to build and analyze locus-specific databases. <i>Human Mutation</i> , 2000 , 15, 86-94	4.7	159
88	Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. <i>Journal of Pathology</i> , 2000 , 192, 52-7	9.4	51
87	Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interactions with the mdm2 protein. <i>Journal of Immunological Methods</i> , 2000 , 244, 17-28	2.5	12
86	Serum p53 antibodies: predictors of survival in small-cell lung cancer?. <i>British Journal of Cancer</i> , 2000 , 83, 1418-24	8.7	27
85	p53 Antibodies in the sera of patients with various types of cancer: a review. <i>Cancer Research</i> , 2000 , 60, 1777-88	10.1	380
84	p53 mutation as a genetic trait of typical medullary breast carcinoma. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 641-3	9.7	58
83	Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. <i>Oncogene</i> , 1999 , 18, 4699-709	9.2	19
82	Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. <i>Oncogene</i> , 1999 , 18, 3553-63	9.2	110
81	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome. <i>International Journal of Cancer</i> , 1999 , 82, 17-22	7.5	5
80	Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1999 , 26, 1672-5	4.1	11
79	Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?. <i>Breast Cancer Research and Treatment</i> , 1998 , 47, 47-55	4.4	35
78	Regulation of the specific DNA binding activity of <i>Xenopus laevis</i> p53: evidence for conserved regulation through the carboxy-terminus of the protein. <i>Oncogene</i> , 1998 , 16, 883-90	9.2	17
77	p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. <i>International Journal of Cancer</i> , 1998 , 78, 390-1	7.5	35
76	Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. <i>British Journal of Haematology</i> , 1998 , 100, 184-6	4.5	3
75	p53 mutations in BRCA1-associated familial breast cancer. <i>Lancet, The</i> , 1998 , 352, 622	4.0	11
74	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1998 , 26, 269-70	20.1	113
73	Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1998 , 26, 198-9	20.1	29

72	p53 gene mutation: software and database. <i>Nucleic Acids Research</i> , 1998 , 26, 200-4	20.1	125
71	Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. <i>Transplantation</i> , 1998 , 66, 667-70	1.8	46
70	The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis 1998 , 221-230		
69	Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. <i>Clinical Cancer Research</i> , 1998 , 4, 1359-66	12.9	58
68	Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. <i>Nucleic Acids Research</i> , 1997 , 25, 151-7	20.1	273
67	p53 and APC gene mutations: software and databases. <i>Nucleic Acids Research</i> , 1997 , 25, 138	20.1	15
66	Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and both the lacI and lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1997 , 25, 136-7	20.1	22
65	Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. <i>Gut</i> , 1997 , 40, 356-61	6.2	67
64	Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. <i>Oncogene</i> , 1997 , 14, 1117-22	9.2	135
63	A functional analysis of p53 during early development of <i>Xenopus laevis</i> . <i>Oncogene</i> , 1997 , 15, 2191-9	9.2	26
62	P53 gene alterations in human tumors: perspectives for cancer control. <i>Recent Results in Cancer Research</i> , 1997 , 143, 369-89	1.5	42
61	Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. <i>Blood</i> , 1997 , 90, 766-75	2.2	71
60	Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. <i>Journal of the National Cancer Institute</i> , 1996 , 88, 1228-33	9.7	75
59	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1996 , 24, 121-4	20.1	199
58	The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. <i>Trends in Molecular Medicine</i> , 1996 , 2, 32-7		48
57	ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. <i>FEBS Letters</i> , 1996 , 385, 34-8	3.8	37
56	Structural aspects of the p53 protein in relation to gene evolution: a second look. <i>Journal of Molecular Biology</i> , 1996 , 260, 623-37	6.5	186
55	Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. <i>Human Mutation</i> , 1996 , 7, 202-13	4.7	31

54	The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. <i>Trends in Immunology</i> , 1996 , 17, 354-6		92
53	Software and database for the analysis of mutations in the human FBN1 gene. <i>Nucleic Acids Research</i> , 1996 , 24, 137-40	20.1	25
52	p53 gene mutation: software and database. <i>Nucleic Acids Research</i> , 1996 , 24, 147-50	20.1	39
51	Regulation of mutant p53 temperature-sensitive DNA binding. <i>Journal of Biological Chemistry</i> , 1996 , 271, 25468-78	5.4	81
50	Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1996 , 24, 119-20	20.1	24
49	Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. <i>Nucleic Acids Research</i> , 1996 , 24, 141-6	20.1	351
48	p53 Autoantibodies 1996 , 595-599		
47	Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. <i>Anticancer Research</i> , 1996 , 16, 2385-8	2.3	16
46	Serum p53 antibodies as early markers of lung cancer. <i>Nature Medicine</i> , 1995 , 1, 701-2	50.5	269
45	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. <i>Gut</i> , 1995 , 36, 455-8	19.2	37
44	p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 1342-6	11.5	45
43	Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. <i>Lancet, The</i> , 1995 , 345, 621-2	40	118
42	The p53 tumor suppressor gene. <i>Advances in Genome Biology</i> , 1995 , 3, 55-141		0
41	Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. <i>European Journal of Immunology</i> , 1995 , 25, 1765-9	6.1	81
40	p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. <i>International Journal of Cancer</i> , 1995 , 64, 176-81	7.5	69
39	p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. <i>Oncogene</i> , 1995 , 10, 9-17	9.2	47
38	Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved. <i>Oncogene</i> , 1995 , 10, 779-84	9.2	12
37	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.. <i>EMBO Journal</i> , 1994 , 13, 3496-3504	13	150

36	Detection and Sequencing of p53 Gene Mutations in Bronchial Biopsy Samples in Patients With Lung Cancer. <i>Chest</i> , 1994 , 106, 1309-1310	5.3	
35	Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. <i>Genes Chromosomes and Cancer</i> , 1994 , 11, 119-25	5	67
34	Multifactorial analysis of p53 alteration in human cancer: a review. <i>International Journal of Cancer</i> , 1994 , 57, 1-9	7.5	250
33	Cancer and the heat shock response. <i>European Journal of Cancer</i> , 1994 , 30A, 1884-91	7.5	110
32	Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1994 , 307, 375-86	3.3	82
31	Effects of electrical brainstem stimulation on tinnitus. <i>Acta Oto-Laryngologica</i> , 1994 , 114, 135-40	1.6	55
30	Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. <i>British Journal of Cancer</i> , 1994 , 69, 809-16	8.7	129
29	Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. <i>Oncogene</i> , 1994 , 9, 3689-94	9.2	49
28	p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. <i>Modern Pathology</i> , 1994 , 7, 853-9	9.8	26
27	Database and software for the analysis of mutations in the human p53 gene. <i>Cancer Research</i> , 1994 , 54, 4454-60	10.1	56
26	3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation. <i>Cancer Research</i> , 1994 , 54, 4502-7	10.1	8
25	Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. <i>Oncogene</i> , 1994 , 9, 2071-6	9.2	45
24	Functional characterization of <i>Xenopus laevis</i> p53: evidence of temperature-sensitive transactivation but not of repression. <i>Journal of Virology</i> , 1994 , 68, 7178-87	6.6	8
23	Database and software for the analysis of mutations at the human p53 gene. <i>Nucleic Acids Research</i> , 1994 , 22, 3549-50	20.1	23
22	Database of p53 gene somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1994 , 22, 3551-5	20.1	561
21	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. <i>EMBO Journal</i> , 1994 , 13, 3496-504	13	61
20	Stabilization and expression of high levels of p53 during early development in <i>Xenopus laevis</i> . <i>Developmental Biology</i> , 1993 , 159, 163-72	3.1	43
19	Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. <i>Bulletin Du Cancer</i> , 1993 , 80, 102-10	2.4	11

18	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. <i>Cancer Research</i> , 1993 , 53, 5872-6	10.1	132
17	The cDNA cloning and immunological characterization of hamster p53. <i>Gene</i> , 1992 , 112, 247-50	3.8	22
16	Rainbow trout p53: cDNA cloning and biochemical characterization. <i>Gene</i> , 1992 , 112, 241-5	3.8	67
15	Absence of p53 germ-line mutations in bilateral breast cancer patients. <i>Human Genetics</i> , 1992 , 89, 250-26.3		23
14	TP53 tumor suppressor gene: a model for investigating human mutagenesis. <i>Genes Chromosomes and Cancer</i> , 1992 , 4, 1-15	5	43 ¹
13	The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. <i>Cancer Research</i> , 1992 , 52, 6380-4	10.1	201
12	Structural aspects of the p53 protein in relation to gene evolution. <i>Oncogene</i> , 1990 , 5, 945-52	9.2	408
11	Evolutionary conservation of the biochemical properties of p53: specific interaction of <i>Xenopus laevis</i> p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70. <i>Journal of Virology</i> , 1989 , 63, 3894-901	6.6	31
10	Translocation of a store of maternal cytoplasmic c-myc protein into nuclei during early development. <i>Molecular and Cellular Biology</i> , 1989 , 9, 5395-5403	4.8	21
9	Characterization of a bovine acidic FGF cDNA clone and its expression in brain and retina. <i>FEBS Letters</i> , 1988 , 242, 41-6	3.8	32
8	Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. <i>Nucleic Acids Research</i> , 1988 , 16, 11384	20.1	90
7	Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein. <i>Nucleic Acids Research</i> , 1988 , 16, 11383	20.1	36
6	Cloning and characterization of a cDNA from <i>Xenopus laevis</i> coding for a protein homologous to human and murine p53. <i>Oncogene</i> , 1987 , 1, 71-8	9.2	130
5	DNA-binding properties of the major structural protein of simian virus 40. <i>Journal of Virology</i> , 1986 , 59, 740-2	6.6	33
4	Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. <i>Experimental Cell Research</i> , 1985 , 160, 83-94	4.2	85
3	Stimulation of rat liver alpha- and beta-type DNA polymerases by an homologous DNA-unwinding protein. <i>FEBS Letters</i> , 1977 , 79, 160-4	3.8	25
2	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. <i>SSRN Electronic Journal</i> ,	1	1
1	Ultra-sensitive sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan		1

